Stiripentol: efficacy and tolerability in children with epilepsy
about
Stiripentol for focal refractory epilepsyAntiepileptic drugs for the treatment of infants with severe myoclonic epilepsyAntiepileptic drugs for the treatment of severe myoclonic epilepsy in infancyStiripentol for focal refractory epilepsyStiripentol for focal refractory epilepsyAntiepileptic drugs for the treatment of severe myoclonic epilepsy in infancyPharmacological characterization of an antisense knockdown zebrafish model of Dravet syndrome: inhibition of epileptic seizures by the serotonin agonist fenfluramineStiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channelsStiripentolThe pharmacologic treatment of Dravet syndromeSafety and tolerability of antiepileptic drug treatment in children with epilepsy.Stiripentol : in severe myoclonic epilepsy of infancy (dravet syndrome).Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs.A revisited strategy for antiepileptic drug development in children: designing an initial exploratory step.Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human.Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome.Stiripentol.Synergistic GABA-enhancing therapy against seizures in a mouse model of Dravet syndrome.Current therapeutic procedures in Dravet syndrome.Neurogenetic disorders and treatment of associated seizures.The long-term safety of antiepileptic drugs.Diagnosis and management of epileptic encephalopathies in children.Population Pharmacokinetics of Stiripentol in Paediatric Patients with Dravet Syndrome Treated with Stiripentol, Valproate and Clobazam Combination Therapy.Pharmacological considerations in the use of stiripentol for the treatment of epilepsy.Stiripentol and vigabatrin current roles in the treatment of epilepsy.Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy.Current Treatment Options for Early-Onset Pediatric Epileptic Encephalopathies.Pharmacogenomics in epilepsy.Stiripentol in the Management of Epilepsy.Interactions between modulators of the GABA(A) receptor: Stiripentol and benzodiazepinesSevere myoclonic epilepsy in infancy: toward an optimal treatment.Characterization of the anticonvulsant, behavioral and pharmacokinetic interaction profiles of stiripentol in combination with clonazepam, ethosuximide, phenobarbital, and valproate using isobolographic analysis.Stiripentol exhibits higher anticonvulsant properties in the immature than in the mature rat brain.
P2860
Q24186440-3AAD5522-7E8A-4520-B521-661414101626Q24186474-584E2CDF-8883-4AC3-93CC-EA0FEBC7C6E0Q24198031-7DE32C30-94C8-4197-A929-BEB32B43B2E7Q24198833-9028448C-B068-4177-ABC2-C5993637F248Q24200888-4318EEE0-A3C2-42D0-B11A-B3866206D346Q24202411-5894800A-6FE9-4558-B534-E1D41F7D03F3Q27308068-09179FB7-725A-4506-BE26-2AB5EC1165BDQ28237504-6D4C8D09-6737-443B-B61C-5786E8F6BBBDQ28261980-80F02759-1A36-47CD-A6FE-B0818EE1DC37Q29013852-B517660A-F4DE-4DF1-970B-0B77994C7F82Q34281872-06D7B5E0-268A-46E7-AAE9-BE8B2E12F3DCQ34302354-E3F2280B-C14E-473F-9770-12BA6D2B4FFAQ34559174-82EBC15D-2DB5-43BA-B956-4D49017CAD96Q34560399-322087C6-14B9-4E46-896E-CF373EC550C1Q35825816-40EAAADB-E1F6-40DC-AD1B-9573B9F97CBFQ36245909-951D1B62-DD68-4550-B8FE-97CB3ED0F22EQ36697489-DD7BCC8D-4DB9-434A-A73B-F9F85AAF58A6Q36776559-89DA16B2-7912-4AC3-9D82-E3A914E8BD36Q37866832-7B438E7D-C072-4A51-81A0-FF7C22009A5DQ38080786-D4D9064E-8942-4744-8FA7-1F29E100C794Q38106856-638C7252-55F8-4EDB-A8B7-407029BEE55BQ38130936-8C695121-5833-4850-AE0D-F52DCFF43623Q38371961-331DDE0F-37D5-4B80-83C8-B74398DCAAFCQ38738877-BAFCEBCD-F124-4764-AA4D-2B32AB2F03CEQ38757727-7D7F1DAA-DE22-4321-8F25-F6E9579CF37BQ38776903-955741CB-F20F-478F-8F01-2E5D062EE711Q38946719-9C46E63E-83BC-4ED8-A907-02AD4B18EE3DQ39084353-1AA81531-0E14-4848-842F-725944974FABQ39256887-72AF305C-7D33-45FC-B4FE-57AC0D79DC31Q39607659-A0CA2540-473C-4F7D-90D2-EAC287CFD2C2Q40521728-11DE4A70-D0AA-4093-87D1-1B819E93ED7FQ48364123-1DBCBEA9-BC1C-40A7-BA70-D042FF284B6CQ48940505-5C53A62F-E04E-453C-BD88-1C3E2CF0D730
P2860
Stiripentol: efficacy and tolerability in children with epilepsy
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Stiripentol: efficacy and tolerability in children with epilepsy
@ast
Stiripentol: efficacy and tolerability in children with epilepsy
@en
Stiripentol: efficacy and tolerability in children with epilepsy
@nl
type
label
Stiripentol: efficacy and tolerability in children with epilepsy
@ast
Stiripentol: efficacy and tolerability in children with epilepsy
@en
Stiripentol: efficacy and tolerability in children with epilepsy
@nl
prefLabel
Stiripentol: efficacy and tolerability in children with epilepsy
@ast
Stiripentol: efficacy and tolerability in children with epilepsy
@en
Stiripentol: efficacy and tolerability in children with epilepsy
@nl
P2093
P1433
P1476
Stiripentol: efficacy and tolerability in children with epilepsy
@en
P2093
P2860
P304
P356
10.1111/J.1528-1157.1999.TB02048.X
P407
P577
1999-11-01T00:00:00Z